{"id":952838,"date":"2026-04-20T08:18:01","date_gmt":"2026-04-20T12:18:01","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/dana-farber-cancer-institute-study-demonstrates-predictive-value-of-ignite-proteomics-rppa-platform-for-t-dxd-enhertu-therapy-in-metastatic-breast-cancer-patients\/"},"modified":"2026-04-20T08:18:01","modified_gmt":"2026-04-20T12:18:01","slug":"dana-farber-cancer-institute-study-demonstrates-predictive-value-of-ignite-proteomics-rppa-platform-for-t-dxd-enhertu-therapy-in-metastatic-breast-cancer-patients","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/dana-farber-cancer-institute-study-demonstrates-predictive-value-of-ignite-proteomics-rppa-platform-for-t-dxd-enhertu-therapy-in-metastatic-breast-cancer-patients\/","title":{"rendered":"Dana-Farber Cancer Institute Study Demonstrates Predictive Value of Ignite Proteomics\u2019 RPPA Platform for T-DXd (Enhertu\u00ae) Therapy in Metastatic Breast Cancer Patients"},"content":{"rendered":"

<\/p>\n

Dana-Farber Cancer Institute Study Demonstrates Predictive Value of Ignite Proteomics\u2019 RPPA Platform for T-DXd (Enhertu\u00ae) Therapy in Metastatic Breast Cancer Patients<\/b><\/p>\n

Peer-reviewed study finds standard HER2 IHC testing shows limited predictive value for T-DXd while Ignite\u2019s platform \u2014 the only commercially available multiplex assay in the study\u2014demonstrates predictive value for patient outcomes<\/i><\/p>\n

MOUNTAIN VIEW, Calif.–(BUSINESS WIRE<\/a>)–
\nAditxt, Inc. (Nasdaq: ADTX) (\u201cAditxt\u201d or the \u201cCompany\u201d), a social innovation platform accelerating promising health innovations, today announced that its precision oncology subsidiary, Ignite Proteomics, LLC (\u201cIgnite\u201d or \u201cIgnite Proteomics\u201d), has been featured in a peer-reviewed study published online ahead of print in npj Precision Oncology<\/i>, a Nature journal. The study, led by investigators at Dana-Farber Cancer Institute, evaluated outcomes among patients with metastatic breast cancer treated with trastuzumab deruxtecan (T-DXd, marketed as Enhertu\u00ae by AstraZeneca and Daiichi Sankyo) and assessed multiple quantitative HER2-related assays for their association with treatment outcomes.<\/p>\n

\nWhile conventional HER2 immunohistochemistry (IHC) showed some association with outcomes in the broader patient population, the study found that quantitative HER2-related assays provided more granular predictive information in several matched biomarker sub-cohorts. In those sub-cohorts, traditional IHC classification often showed limited predictive value compared with quantitative approaches. Ignite\u2019s Reverse Phase Protein Array (RPPA) platform, the only commercially available multiplex assay in the study, was one of the quantitative methods that demonstrated meaningful predictive value for patient outcomes.<\/p>\n

\nT-DXd is an approved treatment option for a broad population of patients with metastatic breast cancer, yet there is currently no reliable way to predict which patients will respond.<\/p>\n

\n\u201cAccording to several studies, approximately 40% of cancers do not respond to the FDA approved therapy at front line in a metastatic setting,\u201d said Jeff Busch, Chief Executive Officer of Ignite Proteomics. In oncology, published research and institutional analyses have shown that approved therapies often fail to benefit a substantial portion of the patients who receive them. A 2017 study published in the BMJ<\/a> reported that 57% of cancer drug indications approved by the European Medicines Agency entered the market without evidence of improved survival or quality-of-life benefit. MIT researchers have noted<\/a> that targeted tyrosine kinase inhibitors typically work for only 40% to 80% of patients expected to respond. Johns Hopkins has reported<\/a> that only 15% to 20% of patients achieve durable results with immunotherapy.<\/p>\n

\nIgnite\u2019s RPPA platform measures multiple protein biomarkers, including pathway activation and payload-relevant markers, from a single tumor sample. In the Dana-Farber study, Ignite\u2019s platform was the only commercially available multiplex assay evaluated and demonstrated predictive value in matched biomarker cohorts where conventional HER2 IHC showed limitations. Notably, the study found that TOPO1 expression, the target of T-DXd\u2019s cytotoxic payload, was detectable by Ignite\u2019s platform in certain HER2-negative patients, highlighting the potential value of measuring tumor biology beyond HER2 expression alone. Ignite\u2019s assay is CLIA-certified, CAP-accredited, listed on the Medicare Clinical Laboratory Fee Schedule under AMA CPT code PLA 0249U, and orderable today on standard biopsy tissue.<\/p>\n

\n\u201cCancer therapy has made extraordinary progress, but oncology still has a treatment-selection problem,\u201d added Busch. \u201cToo many patients receive therapies without enough information about whether those therapies are likely to work for their tumor biology. That is not an indictment of the drugs. These are powerful therapies. The issue is that cancer is complex, and single-marker testing often does not capture the functional biology that drives response or resistance. Ignite\u2019s RPPA platform was built to address that gap by measuring multiple proteins, pathway activation, and payload-relevant biology from the same tumor sample. In this study, one of the world\u2019s leading breast cancer research teams evaluated our platform alongside standard testing, and our platform demonstrated predictive value where conventional testing had limitations. That is the opportunity: better data, better treatment selection, and fewer patients receiving therapies that were never likely to help them.\u201d<\/p>\n

\n\u201cThis publication represents an important milestone for our subsidiary Ignite and reflects the strength of Aditxt\u2019s model of advancing and scaling impactful health innovations,\u201d said Amro Albanna, Co-Founder and Chief Executive Officer of Aditxt. \u201cPeer-reviewed clinical evidence from one of the world\u2019s leading cancer research institutions is key to accelerating the commercialization of this platform and expanding access to it for millions of patients making treatment decisions without clear guidance on what will work. Our goal is to help ensure that more patients receive the right therapy at the right time, with the potential to improve outcomes and make a meaningful difference in people\u2019s lives.\u201d<\/p>\n

\nThe full study is available open access at: https:\/\/doi.org\/10.1038\/s41698-026-01365-6<\/a><\/p>\n

About Ignite Proteomics, LLC<\/b><\/p>\n

\nIgnite Proteomics delivers pathway\u2011level protein analytics to guide precision oncology. Operating a CLIA\u2011certified, CAP\u2011accredited laboratory, Ignite’s clinical RPPA assay quantifies 32 phospho- and total-protein biomarkers from limited biopsy material to support oncology research and clinical decision making.<\/p>\n

About Aditxt, Inc.<\/b><\/p>\n

\nAditxt, Inc. is a social innovation platform accelerating promising health innovations. Aditxt\u2019s ecosystem of research institutions, industry partners, and shareholders collaboratively drives its mission to “Make Promising Innovations Possible Together.” The innovation platform is the cornerstone of Aditxt\u2019s strategy, where multiple disciplines drive disruptive growth and address significant societal challenges. Aditxt operates a unique model that democratizes innovation, ensures every stakeholder\u2019s voice is heard and valued, and empowers collective progress. The Company currently operates four programs focused on autoimmunity, cancer and early disease detection, infectious diseases and women\u2019s health.<\/p>\n

Forward-Looking Statements<\/b><\/p>\n

\nThis press release includes “forward-looking statements,” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “aim,” “believe,” “could,” “expect,” “intend,” “may,” “plan,” “potential,” “seek,” “will,” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding the significance of the published study, Ignite\u2019s commercialization plans, the potential clinical utility of its platform, expected collaborations, publications, reimbursement, adoption, and international expansion. You are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements are disclosed in each company\u2019s SEC filings, including Aditxt\u2019s Annual Report on Form 10-K and any subsequent Form 10-Q filings, including the most recent filed on November 18, 2025. All forward-looking statements are expressly qualified in their entirety by such factors. Aditxt undertakes no duty to update any forward-looking statement except as required by law.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20260420307974\/en\/<\/a><\/span><\/p>\n

Aditxt, Inc.
\n
Investor Relations
\n
<\/b>ir@aditxt.com<\/b><\/a><\/p>\n

KEYWORDS:<\/b> California United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Oncology Health Clinical Trials Research Science Pharmaceutical Biotechnology<\/p>\n

MEDIA:<\/b><\/p>\n\n","protected":false},"excerpt":{"rendered":"

Dana-Farber Cancer Institute Study Demonstrates Predictive Value of Ignite Proteomics\u2019 RPPA Platform for T-DXd (Enhertu\u00ae) Therapy in Metastatic Breast Cancer Patients Peer-reviewed study finds standard HER2 IHC testing shows limited predictive value for T-DXd while Ignite\u2019s platform \u2014 the only commercially available multiplex assay in the study\u2014demonstrates predictive value for patient outcomes MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)– Aditxt, Inc. (Nasdaq: ADTX) (\u201cAditxt\u201d or the \u201cCompany\u201d), a social innovation platform accelerating promising health innovations, today announced that its precision oncology subsidiary, Ignite Proteomics, LLC (\u201cIgnite\u201d or \u201cIgnite Proteomics\u201d), has been featured in a peer-reviewed study published online ahead of print in npj Precision Oncology, a Nature journal. The study, led by investigators at Dana-Farber Cancer Institute, evaluated outcomes among patients with metastatic … <\/p>\n

Continue reading “Dana-Farber Cancer Institute Study Demonstrates Predictive Value of Ignite Proteomics\u2019 RPPA Platform for T-DXd (Enhertu\u00ae) Therapy in Metastatic Breast Cancer Patients”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-952838","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nDana-Farber Cancer Institute Study Demonstrates Predictive Value of Ignite Proteomics\u2019 RPPA Platform for T-DXd (Enhertu\u00ae) Therapy in Metastatic Breast Cancer Patients - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/dana-farber-cancer-institute-study-demonstrates-predictive-value-of-ignite-proteomics-rppa-platform-for-t-dxd-enhertu-therapy-in-metastatic-breast-cancer-patients\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Dana-Farber Cancer Institute Study Demonstrates Predictive Value of Ignite Proteomics\u2019 RPPA Platform for T-DXd (Enhertu\u00ae) Therapy in Metastatic Breast Cancer Patients - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Dana-Farber Cancer Institute Study Demonstrates Predictive Value of Ignite Proteomics\u2019 RPPA Platform for T-DXd (Enhertu\u00ae) Therapy in Metastatic Breast Cancer Patients Peer-reviewed study finds standard HER2 IHC testing shows limited predictive value for T-DXd while Ignite\u2019s platform \u2014 the only commercially available multiplex assay in the study\u2014demonstrates predictive value for patient outcomes MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)– Aditxt, Inc. (Nasdaq: ADTX) (\u201cAditxt\u201d or the \u201cCompany\u201d), a social innovation platform accelerating promising health innovations, today announced that its precision oncology subsidiary, Ignite Proteomics, LLC (\u201cIgnite\u201d or \u201cIgnite Proteomics\u201d), has been featured in a peer-reviewed study published online ahead of print in npj Precision Oncology, a Nature journal. The study, led by investigators at Dana-Farber Cancer Institute, evaluated outcomes among patients with metastatic … Continue reading "Dana-Farber Cancer Institute Study Demonstrates Predictive Value of Ignite Proteomics\u2019 RPPA Platform for T-DXd (Enhertu\u00ae) Therapy in Metastatic Breast Cancer Patients"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/dana-farber-cancer-institute-study-demonstrates-predictive-value-of-ignite-proteomics-rppa-platform-for-t-dxd-enhertu-therapy-in-metastatic-breast-cancer-patients\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-20T12:18:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260420307974r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dana-farber-cancer-institute-study-demonstrates-predictive-value-of-ignite-proteomics-rppa-platform-for-t-dxd-enhertu-therapy-in-metastatic-breast-cancer-patients\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dana-farber-cancer-institute-study-demonstrates-predictive-value-of-ignite-proteomics-rppa-platform-for-t-dxd-enhertu-therapy-in-metastatic-breast-cancer-patients\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Dana-Farber Cancer Institute Study Demonstrates Predictive Value of Ignite Proteomics\u2019 RPPA Platform for T-DXd (Enhertu\u00ae) Therapy in Metastatic Breast Cancer Patients\",\"datePublished\":\"2026-04-20T12:18:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dana-farber-cancer-institute-study-demonstrates-predictive-value-of-ignite-proteomics-rppa-platform-for-t-dxd-enhertu-therapy-in-metastatic-breast-cancer-patients\\\/\"},\"wordCount\":1142,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dana-farber-cancer-institute-study-demonstrates-predictive-value-of-ignite-proteomics-rppa-platform-for-t-dxd-enhertu-therapy-in-metastatic-breast-cancer-patients\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260420307974r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dana-farber-cancer-institute-study-demonstrates-predictive-value-of-ignite-proteomics-rppa-platform-for-t-dxd-enhertu-therapy-in-metastatic-breast-cancer-patients\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dana-farber-cancer-institute-study-demonstrates-predictive-value-of-ignite-proteomics-rppa-platform-for-t-dxd-enhertu-therapy-in-metastatic-breast-cancer-patients\\\/\",\"name\":\"Dana-Farber Cancer Institute Study Demonstrates Predictive Value of Ignite Proteomics\u2019 RPPA Platform for T-DXd (Enhertu\u00ae) Therapy in Metastatic Breast Cancer Patients - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dana-farber-cancer-institute-study-demonstrates-predictive-value-of-ignite-proteomics-rppa-platform-for-t-dxd-enhertu-therapy-in-metastatic-breast-cancer-patients\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dana-farber-cancer-institute-study-demonstrates-predictive-value-of-ignite-proteomics-rppa-platform-for-t-dxd-enhertu-therapy-in-metastatic-breast-cancer-patients\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260420307974r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2026-04-20T12:18:01+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dana-farber-cancer-institute-study-demonstrates-predictive-value-of-ignite-proteomics-rppa-platform-for-t-dxd-enhertu-therapy-in-metastatic-breast-cancer-patients\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dana-farber-cancer-institute-study-demonstrates-predictive-value-of-ignite-proteomics-rppa-platform-for-t-dxd-enhertu-therapy-in-metastatic-breast-cancer-patients\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dana-farber-cancer-institute-study-demonstrates-predictive-value-of-ignite-proteomics-rppa-platform-for-t-dxd-enhertu-therapy-in-metastatic-breast-cancer-patients\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260420307974r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260420307974r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dana-farber-cancer-institute-study-demonstrates-predictive-value-of-ignite-proteomics-rppa-platform-for-t-dxd-enhertu-therapy-in-metastatic-breast-cancer-patients\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Dana-Farber Cancer Institute Study Demonstrates Predictive Value of Ignite Proteomics\u2019 RPPA Platform for T-DXd (Enhertu\u00ae) Therapy in Metastatic Breast Cancer Patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Dana-Farber Cancer Institute Study Demonstrates Predictive Value of Ignite Proteomics\u2019 RPPA Platform for T-DXd (Enhertu\u00ae) Therapy in Metastatic Breast Cancer Patients - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/dana-farber-cancer-institute-study-demonstrates-predictive-value-of-ignite-proteomics-rppa-platform-for-t-dxd-enhertu-therapy-in-metastatic-breast-cancer-patients\/","og_locale":"en_US","og_type":"article","og_title":"Dana-Farber Cancer Institute Study Demonstrates Predictive Value of Ignite Proteomics\u2019 RPPA Platform for T-DXd (Enhertu\u00ae) Therapy in Metastatic Breast Cancer Patients - Market Newsdesk","og_description":"Dana-Farber Cancer Institute Study Demonstrates Predictive Value of Ignite Proteomics\u2019 RPPA Platform for T-DXd (Enhertu\u00ae) Therapy in Metastatic Breast Cancer Patients Peer-reviewed study finds standard HER2 IHC testing shows limited predictive value for T-DXd while Ignite\u2019s platform \u2014 the only commercially available multiplex assay in the study\u2014demonstrates predictive value for patient outcomes MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)– Aditxt, Inc. (Nasdaq: ADTX) (\u201cAditxt\u201d or the \u201cCompany\u201d), a social innovation platform accelerating promising health innovations, today announced that its precision oncology subsidiary, Ignite Proteomics, LLC (\u201cIgnite\u201d or \u201cIgnite Proteomics\u201d), has been featured in a peer-reviewed study published online ahead of print in npj Precision Oncology, a Nature journal. The study, led by investigators at Dana-Farber Cancer Institute, evaluated outcomes among patients with metastatic … Continue reading \"Dana-Farber Cancer Institute Study Demonstrates Predictive Value of Ignite Proteomics\u2019 RPPA Platform for T-DXd (Enhertu\u00ae) Therapy in Metastatic Breast Cancer Patients\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/dana-farber-cancer-institute-study-demonstrates-predictive-value-of-ignite-proteomics-rppa-platform-for-t-dxd-enhertu-therapy-in-metastatic-breast-cancer-patients\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-20T12:18:01+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260420307974r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dana-farber-cancer-institute-study-demonstrates-predictive-value-of-ignite-proteomics-rppa-platform-for-t-dxd-enhertu-therapy-in-metastatic-breast-cancer-patients\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dana-farber-cancer-institute-study-demonstrates-predictive-value-of-ignite-proteomics-rppa-platform-for-t-dxd-enhertu-therapy-in-metastatic-breast-cancer-patients\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Dana-Farber Cancer Institute Study Demonstrates Predictive Value of Ignite Proteomics\u2019 RPPA Platform for T-DXd (Enhertu\u00ae) Therapy in Metastatic Breast Cancer Patients","datePublished":"2026-04-20T12:18:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dana-farber-cancer-institute-study-demonstrates-predictive-value-of-ignite-proteomics-rppa-platform-for-t-dxd-enhertu-therapy-in-metastatic-breast-cancer-patients\/"},"wordCount":1142,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dana-farber-cancer-institute-study-demonstrates-predictive-value-of-ignite-proteomics-rppa-platform-for-t-dxd-enhertu-therapy-in-metastatic-breast-cancer-patients\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260420307974r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dana-farber-cancer-institute-study-demonstrates-predictive-value-of-ignite-proteomics-rppa-platform-for-t-dxd-enhertu-therapy-in-metastatic-breast-cancer-patients\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/dana-farber-cancer-institute-study-demonstrates-predictive-value-of-ignite-proteomics-rppa-platform-for-t-dxd-enhertu-therapy-in-metastatic-breast-cancer-patients\/","name":"Dana-Farber Cancer Institute Study Demonstrates Predictive Value of Ignite Proteomics\u2019 RPPA Platform for T-DXd (Enhertu\u00ae) Therapy in Metastatic Breast Cancer Patients - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dana-farber-cancer-institute-study-demonstrates-predictive-value-of-ignite-proteomics-rppa-platform-for-t-dxd-enhertu-therapy-in-metastatic-breast-cancer-patients\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dana-farber-cancer-institute-study-demonstrates-predictive-value-of-ignite-proteomics-rppa-platform-for-t-dxd-enhertu-therapy-in-metastatic-breast-cancer-patients\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260420307974r1&sid=flmnd&distro=nx&lang=en","datePublished":"2026-04-20T12:18:01+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dana-farber-cancer-institute-study-demonstrates-predictive-value-of-ignite-proteomics-rppa-platform-for-t-dxd-enhertu-therapy-in-metastatic-breast-cancer-patients\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/dana-farber-cancer-institute-study-demonstrates-predictive-value-of-ignite-proteomics-rppa-platform-for-t-dxd-enhertu-therapy-in-metastatic-breast-cancer-patients\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dana-farber-cancer-institute-study-demonstrates-predictive-value-of-ignite-proteomics-rppa-platform-for-t-dxd-enhertu-therapy-in-metastatic-breast-cancer-patients\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260420307974r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260420307974r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dana-farber-cancer-institute-study-demonstrates-predictive-value-of-ignite-proteomics-rppa-platform-for-t-dxd-enhertu-therapy-in-metastatic-breast-cancer-patients\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Dana-Farber Cancer Institute Study Demonstrates Predictive Value of Ignite Proteomics\u2019 RPPA Platform for T-DXd (Enhertu\u00ae) Therapy in Metastatic Breast Cancer Patients"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/952838","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=952838"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/952838\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=952838"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=952838"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=952838"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}